Brokerages Set Envista Holdings Co. (NYSE:NVST) PT at $20.71

Shares of Envista Holdings Co. (NYSE:NVST) have earned an average rating of “Hold” from the fifteen analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $20.71.

A number of equities research analysts recently commented on the stock. Leerink Partners upgraded shares of Envista from an “underperform” rating to a “market perform” rating and raised their price objective for the stock from $16.00 to $23.00 in a report on Thursday, October 31st. Piper Sandler boosted their price target on Envista from $16.00 to $17.00 and gave the company a “neutral” rating in a report on Thursday, October 31st. JPMorgan Chase & Co. downgraded Envista from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $23.00 to $16.00 in a report on Thursday, August 8th. Leerink Partnrs upgraded Envista from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 31st. Finally, Robert W. Baird raised their price target on shares of Envista from $17.00 to $22.00 and gave the stock a “neutral” rating in a research note on Thursday, October 31st.

Hedge Funds Weigh In On Envista

A number of hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Envista in the 3rd quarter valued at approximately $31,000. GAMMA Investing LLC increased its stake in Envista by 69.8% in the third quarter. GAMMA Investing LLC now owns 1,766 shares of the company’s stock valued at $35,000 after acquiring an additional 726 shares during the last quarter. Huntington National Bank raised its position in Envista by 97.8% during the third quarter. Huntington National Bank now owns 1,919 shares of the company’s stock valued at $38,000 after purchasing an additional 949 shares in the last quarter. Blue Trust Inc. lifted its stake in Envista by 69.7% during the third quarter. Blue Trust Inc. now owns 1,957 shares of the company’s stock worth $39,000 after purchasing an additional 804 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in shares of Envista by 50.8% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 2,161 shares of the company’s stock valued at $43,000 after purchasing an additional 728 shares in the last quarter.

Envista Price Performance

Envista stock opened at $20.52 on Friday. The firm has a market capitalization of $3.53 billion, a P/E ratio of -2.67, a PEG ratio of 2.87 and a beta of 1.30. The business has a 50-day moving average of $18.97 and a 200-day moving average of $18.10. The company has a current ratio of 2.08, a quick ratio of 1.77 and a debt-to-equity ratio of 0.42. Envista has a 1 year low of $15.15 and a 1 year high of $25.64.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, October 30th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.09 by $0.03. The company had revenue of $601.00 million during the quarter, compared to analyst estimates of $590.34 million. Envista had a negative net margin of 53.42% and a positive return on equity of 3.76%. The firm’s revenue was down 4.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.43 EPS. On average, equities analysts anticipate that Envista will post 0.71 EPS for the current year.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.